418 reports of this reaction
3.0% of all DAPTOMYCIN reports
#5 most reported adverse reaction
EOSINOPHILIC PNEUMONIA is the #5 most commonly reported adverse reaction for DAPTOMYCIN, manufactured by APOTEX CORP.. There are 418 FDA adverse event reports linking DAPTOMYCIN to EOSINOPHILIC PNEUMONIA. This represents approximately 3.0% of all 14,068 adverse event reports for this drug.
Patients taking DAPTOMYCIN who experience eosinophilic pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EOSINOPHILIC PNEUMONIA is a less commonly reported adverse event for DAPTOMYCIN, but still significant enough to appear in the safety profile.
In addition to eosinophilic pneumonia, the following adverse reactions have been reported for DAPTOMYCIN:
EOSINOPHILIC PNEUMONIA has been reported as an adverse event in 418 FDA reports for DAPTOMYCIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
EOSINOPHILIC PNEUMONIA accounts for approximately 3.0% of all adverse event reports for DAPTOMYCIN, making it a notable side effect.
If you experience eosinophilic pneumonia while taking DAPTOMYCIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.